Otonomy Stock News

Conference call and webcast today at 4:30 p.m. ET

SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that ma

SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2021 and provide a corporate update at 4:30 p.m. ET on February 28, 2022.

SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will

Otonomy Inc. (NASDAQ:OTIC) concluded the trading at $2.00 on Friday, December 03 with a fall of -3.38% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $2.07 and 5Y monthly beta was reading 2.01 with its price kept floating in the range Otonomy Inc.s (OTIC) $2.00: At This Price, Its Worthwhile Read More »

Geode Capital Management LLC increased its stake in shares of Otonomy, Inc. (NASDAQ:OTIC) by 2.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 427,394 shares of the biopharmaceutical company’s stock after buying an additional 11,204 shares during the period. […]

Zacks Investment Research downgraded shares of Otonomy (NASDAQ:OTIC) from a hold rating to a sell rating in a report published on Tuesday, Zacks.com reports. According to Zacks, Otonomy, Inc. engages in developing and commercializing therapeutics to address unmet medical needs in the otology market. It develops therapeutics for treatment of inner and middle ear disorders. []

SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference. Management will participate in a pre-recorded company fireside chat, which will be available on the conference website beginning at 10 a.m. ET / 7 a.m. PT on November 22, 2021.

Otonomy (OTIC) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pub

SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pr

SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that m

SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the app

Conference call and webcast today at 4:30 p.m. ET

SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will